TrialPloS one2014

miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.

Jakob V Schou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.